Aimei Health Technology (NASDAQ:AFJK), trading on NASDAQ under the ticker AFJK, is a China-based provider of digital healthcare solutions with a focus on medical aesthetics and precision diagnostics. Since its founding in 2015 and headquartered in Beijing, the company has leveraged advanced imaging technologies, artificial intelligence, and cloud-based software to serve hospitals, clinics, and specialty practices. Aimei’s integrated platform aims to improve diagnostic accuracy and treatment outcomes in fields such as dermatology, dental care, and plastic surgery.
Aimei’s core offerings include high-resolution digital imaging systems, AI-driven analysis tools for skin and facial assessment, and patient management software that streamlines clinical workflows. The company’s imaging devices capture detailed anatomical data, while its proprietary algorithms deliver quantitative insights to guide treatment planning. Aimei also develops mobile applications that allow practitioners to monitor patient progress remotely and adjust therapies in real time, enhancing both convenience and continuity of care.
While Aimei’s primary market is mainland China, the company has expanded its footprint into Southeast Asia and select European markets through strategic partnerships and distribution agreements. This geographic diversification supports growing demand for minimally invasive procedures and personalized treatment plans. Aimei works closely with leading academic institutions and medical societies to conduct clinical trials and validate its technology, reinforcing its commitment to evidence-based healthcare.
Under the leadership of CEO Dr. Li Wei, a biomedical engineer with over 20 years of experience in medical imaging, and CFO Zhang Xiaoming, who has steered the company’s financial strategy through periods of growth and public listing, Aimei continues to invest in research and development. The management team emphasizes regulatory compliance and quality control, aiming to maintain high standards in product safety and performance. Looking ahead, Aimei Health Technology seeks to expand its AI capabilities and explore new verticals such as telemedicine and remote surgical guidance.
